Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
5.10
-0.16 (-3.04%)
At close: Mar 28, 2025, 4:00 PM
5.12
+0.02 (0.41%)
After-hours: Mar 28, 2025, 7:51 PM EDT

Company Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome.

In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.

Further, its pipeline includes programs in immunology and inflammation (I&I) indications, oncology, and genetic diseases.

The company has developed QuEEN, a discovery engine, to enable its unique target-centric MGD discovery and development approach and its rational design of MGD product candidates.

It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases.

The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics logo
Country United States
Founded 2019
IPO Date Jun 24, 2021
Industry Biotechnology
Sector Healthcare
Employees 134
CEO Markus Warmuth

Contact Details

Address:
321 Harrison Avenue, Suite 900
Boston, Massachusetts 02118
United States
Phone 617 949 2643
Website monterosatx.com

Stock Details

Ticker Symbol GLUE
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001826457
CUSIP Number 61225M102
ISIN Number US61225M1027
SIC Code 2836

Key Executives

Name Position
Dr. Markus Warmuth M.D. President, Chief Executive Officer and Director
Dr. Filip Janku M.D., Ph.D. Chief Medical Officer
Jennifer Champoux Chief Operating Officer
Dr. John C. Castle Ph.D. Chief Data and Information Officer
Dr. Sharon Townson Ph.D. Chief Scientific Officer
Andrew Funderburk Senior Vice President and Head of IR and Strategic Finance
Philip Nickson J.D., Ph.D. Chief Business and Legal Officer
Magnus Walter DPHIL Senior Vice President of Drug Discovery
Edmund Dunn Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Mar 20, 2025 S-3 Registration statement under Securities Act of 1933
Mar 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 4, 2025 SCHEDULE 13G Filing
Jan 31, 2025 SCHEDULE 13G Filing
Jan 30, 2025 SCHEDULE 13G Filing
Jan 10, 2025 8-K Current Report
Dec 13, 2024 8-K Current Report